All In Biotech

Drug Trial Radar · NCT05037279

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Apr 24, 2024

Primary completion

Feb 2029

Study completion Feb 2029

Sponsor

Lead sponsor
Verity Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Sep 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.

Conditions

  • Bladder Cancer
  • Bladder Cancer Recurrent
  • Neoplasm Recurrence
  • Urothelial Carcinoma Bladder
  • Urothelial Carcinoma Recurrent
  • Non-Invasive Bladder Urothelial Carcinoma

Interventions

  • Bacillus Calmette-Guerin: Strain Russian BCG-IDrug

    * Induction: 80 mg weekly for 6 weeks. * Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months. * Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.

  • Bacillus Calmette-Guerin: Strain TICEDrug

    * Induction: 50 mg weekly for 6 weeks. * Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months. * Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence Free Survival (RFS) at 24 monthsTime frame: 24 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Site 05

    Vancouver, British Columbia, Canada · Recruiting

  • Site 04

    Kingston, Ontario, Canada · Recruiting

  • Site 01

    Toronto, Ontario, Canada · Recruiting

  • Site 02

    Toronto, Ontario, Canada · Not yet recruiting

  • Site 08

    Toronto, Ontario, Canada · Recruiting

  • Site 10

    Montreal, Quebec, Canada · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.